US 11,718,614 B2
Compounds and methods for treatment of hedgehog pathway associated conditions
Fang Du, Suzhou (CN); Xiaowei Hu, Suzhou (CN); and Yugang Liang, Suzhou (CN)
Assigned to Suzhou Mednes Pharma Tech Co., Ltd., Suzhou (CN)
Appl. No. 17/255,413
Filed by Suzhou Mednes Pharma Tech Co., Ltd., Jiangsu (CN)
PCT Filed Jun. 25, 2019, PCT No. PCT/IB2019/055338
§ 371(c)(1), (2) Date Dec. 22, 2020,
PCT Pub. No. WO2020/003119, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/689,470, filed on Jun. 25, 2018.
Prior Publication US 2021/0214353 A1, Jul. 15, 2021
Int. Cl. C07D 209/24 (2006.01); C07D 209/30 (2006.01); C07D 471/04 (2006.01); C07D 235/10 (2006.01); C07D 235/12 (2006.01); C07D 235/16 (2006.01); C07D 403/06 (2006.01); C07D 413/06 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 209/24 (2013.01); C07D 209/30 (2013.01); C07D 235/10 (2013.01); C07D 235/12 (2013.01); C07D 235/16 (2013.01); C07D 403/06 (2013.01); C07D 413/06 (2013.01)] 4 Claims
 
1. A compound of formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
R1 is

OG Complex Work Unit Chemistry
 wherein X is Cl;
R2 is selected from

OG Complex Work Unit Chemistry
 wherein each R14 is independently H or C1-C6 alkyl;
R3 is isopropyl, hydroxyl, or methoxy;
R4 is hydrogen; and
R5 is

OG Complex Work Unit Chemistry